KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Common Equity (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Common Equity for 16 consecutive years, with $27.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 1.29% year-over-year to $27.4 million, compared with a TTM value of $27.4 million through Sep 2025, up 1.29%, and an annual FY2024 reading of $27.4 million, down 6.55% over the prior year.
  • Common Equity was $27.4 million for Q3 2025 at TherapeuticsMD, up from $27.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $35.1 million in Q4 2022 and bottomed at -$140.6 million in Q1 2022.
  • Average Common Equity over 5 years is -$4.0 million, with a median of $27.3 million recorded in 2025.
  • The sharpest move saw Common Equity tumbled 1383.22% in 2022, then skyrocketed 219.68% in 2023.
  • Year by year, Common Equity stood at -$93.6 million in 2021, then surged by 137.54% to $35.1 million in 2022, then fell by 16.66% to $29.3 million in 2023, then fell by 6.55% to $27.4 million in 2024, then grew by 0.27% to $27.4 million in 2025.
  • Business Quant data shows Common Equity for TXMD at $27.4 million in Q3 2025, $27.3 million in Q2 2025, and $26.7 million in Q1 2025.